Explore By Subject Area   

Immuno-Oncology 360°

Date: Mar 24, 2025 - Mar 26, 2025

Location: Boston, MA

2025 Poster Presentation Abstracts & Media

POSTER #1: BlueWhale Bio

Cell-Derived Nanoparticles (CDNPs) Simplify, Accelerate, and Enhance the Consistency of Manufactured CAR T Cells 


First Author: Caimei Zhang
Co-Authors: Chiquita Hanindya, Deeksha Muthumani, Jessica Goldshteyn, Barzan A. Sadiq, Sarah Roussel, Victor Carpio, Gil Joseph, Peter Keller

​​​​​​​Download the Full PDF Abstract

POSTER #2: EvolveImmune

EVOLVE104 is a differentiated T cell engager targeting the novel antigen ULBP2/5/6 for the treatment of squamous tumors and transitional bladder cancers 


First Author: Oksana A. Sergeeva, Ph.D.
Co-Authors: Jennifer Zeiger, M.S.; Colleen Brown, M.S.;  William DeMaria, Ph.D.; Donald Ryan, B.S.; Antonio Ward, Ph.D; Guixian Jin, M.S.; Martin Preyer, Ph.D; Yanhuai Ding, Ph.D; Bruce Andrien, Ph.D; Mark Aimone, MBA; Agnes Meade, Ph.D; Jay S. Fine, Ph.D;  Jeremy S. Myers, Ph.D; Stella Martomo, Ph.D

Funding source & disclosure for all authors: EvolveImmune Therapeutics, Inc. Branford, CT 06405

​​​​​​​Download the Full PDF Abstract

POSTER #3:  GE Healthcare

A Phase 1 dose escalation study to evaluate whole-body CD8+ T cell distribution using an 18F-labeled PET tracer in patients with solid tumors


First Author: Kristen Wangerin, PhD1       
Co-Authors: Derk J. A. de Groot, MD, PhD2 ;Adrienne H. Brouwers, MD, PhD3 ; Erik F. J. de Vries, PhD3 Yaron Raiter, MD1 ; Duncan R. R. Hiscock, PhD1; Elisabeth G. E. de Vries, MD, PhD2    

1GE HealthCare, Pharmaceutical Diagnostics, Pollards Wood, United Kingdom
Dept. of 2Medical Oncology, 3Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, The Netherlands

​​​​​​​Download the Full PDF Abstract

POSTER #4: Imvax

A biologic-device combination platform engineered to induce anti-tumor responses against solid tumors via immunogenic cell death (ICD)


First Author: Jenny Zilberberg, Ph.D.1 
Co-Author: Mark A. Exley, Ph.D.1

1Imvax, Inc., Philadelphia, PA. 

​​​​​​​Download the Full PDF Abstract

POSTER #5:  Promega

Targeted Cell Killing: A Versatile Platform for Cell Therapy, ADC and Cytotoxicity Assays in Diverse Cell Lines


First Author: Gopal B. Krishnan
Co-Authors: Aileen Paguio, Pete Stecha, Yitong Li, Rod Flemming, Vanessa Ott, Nicholas J. Hess, Frank Fan, Brock Binkowski, Julia Gilden, Marjeta Urh, Mei Cong

​​​​​​​Institution for ALL authors: Promega Corporation

​​​​​​​Download the Full PDF Abstract

POSTER #6: Teiko.bio

Reassessing "Fresh" Specimens: Time-Dependent Cell Stability in High-Parameter Cytometry


First Author: Ramji Srinivasan1
Co-Authors: Carly Lancaster, PhD1;Kristina Magee, MD-PhD1 ; Gage Black, PhD1; Lee Leavitt, MS1 ; Justin Jarrell, PhD1 ; Li-Chun Cheng, PhD1

1Teiko, Salt Lake City, UT

​​​​​​​Download the Full PDF Abstract

POSTER #7:  Tempus

Development and validation of an Immune Profile Score (IPS) for stratifying outcomes in a real-world cohort of advanced solid cancer patients


First Author: Alia Zander, PhD1
Co-Authors: Rossin Erbe, PhD1, Yan Liu, PhD1, Ailin Jin, MS1, Seung Won Hyun, PhD1, Sayantoni Mukhopadhyay, MS1, Ben Terdich, BS1, Nirali Patel, MD1, Brett M. Mahon, MD1, Kate Sasser, PhD1, Michelle Ting-Lin, MD1, Halla Nimeiri, MD1, Justin Guinney, PhD1, Kyle Beauchamp, PhD1, Chithra Sangli, MS1, Michelle M. Stein, PhD1, Timothy Taxter, MD1, Timothy A. Chan, MD, PhD3, Sandip Pravin Patel, MD2, Ezra Cohen, MD1,2

1Tempus AI, Inc., Chicago, IL
2Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA.
3Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

​​​​​​​Download the Full PDF Abstract

POSTER #8: Nimbus Therapeutics

Ongoing Phase 1/2 Trial of the HPK1 Inhibitor NDI-101150 as Monotherapy and in Combination with Pembrolizumab: Clinical Safety Update and Renal Cell Carcinoma (RCC) ENicacy Analysis


First Author: David A. Braun1
Co-Authors: David Sommerhalder2, Kurt Demel3, Marcus S. Noel4, Hamid Emamekhoo5, Julio Peguero6, Rama Balaraman7, Ryan H. Moy8, Anita Scheuber9, Joanna Haas9, Daria Chabas9, Xinyan Zhang9, Sue Dasen9, Pavan Kumar9, Scott Daigle9, GiNell Elliott9, Sritama Nath9, Martin Gutierrez10, Sunil Sharma11, Arif Hussain12

1Yale School of Medicine, New Haven, CT, USA; 2NEXT Oncology, San Antonio, TX, USA; 3HealthPartners, St. Louis Park, MN, USA; 4Georgetown University Medical Center – Lombardi Comprehensive Cancer Center, Washington, DC, USA; 5University of Wisconsin Carbone Cancer Center, Madison, WI, USA; 6Oncology Consultants, Houston, TX, USA; 7Florida Cancer Affiliates-US Oncology, Ocala, FL, USA; 8Columbia University Irving Medical Center, New York, NY, USA; 9Nimbus Therapeutics, Boston, MA, USA; 10Hackensack University Medical Center – John Theurer Cancer Center, Hackensack, NJ, USA; 11Honor Health Research Institute, Scottsdale, AZ, USA; 12University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA

​​​​​​​Download the Full PDF Abstract

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.